サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1650988

子宮内膜がん治療の世界市場

Endometrial Cancer Treatment

出版日
ページ情報
英文 192 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.03円
子宮内膜がん治療の世界市場
出版日: 2025年02月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

子宮内膜がん治療の世界市場は2030年までに463億米ドルに達する見込み

2024年に346億米ドルと推定される子宮内膜がん治療の世界市場は、2024～2030年の分析期間にCAGR 5.0％で成長し、2030年には463億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである化学療法は、CAGR 4.7%を記録し、分析期間終了時には313億米ドルに達すると予測されます。ホルモン療法分野の成長率は、分析期間中CAGR 5.5％と推定されます。

米国市場は95億米ドルと推定、中国はCAGR 4.9％で成長予測

米国の子宮内膜がん治療市場は、2024年に95億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに74億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.6%と4.1%と予測されています。欧州では、ドイツがCAGR 4.9%で成長すると予測されています。

世界の子宮内膜がん治療市場- 主要動向と促進要因のまとめ

子宮内膜がん治療は女性の健康と腫瘍学にどのような革命を起こしているか？

子宮内膜がん治療は、最も一般的な婦人科がんの1つである子宮内膜がんを管理するために、ますます効果的で、個別化され、侵襲性の低い選択肢を提供することで、女性の健康と腫瘍学に革命をもたらしています。子宮内膜を侵す子宮内膜がんは、一般的に閉経後の女性で診断され、肥満や高齢化などの要因により罹患率が上昇しています。治療法の進歩により、患者の生存率と生活の質は大幅に改善されています。手術や放射線治療からホルモン療法や分子標的治療まで、子宮内膜がんの治療は急速に進化しています。手術技術、特に腹腔鏡手術やロボット支援手術のような低侵襲手術は、より短い回復期間とより少ない合併症でがん組織を正確に除去することを可能にします。さらに、標的療法と免疫療法の出現は、進行または再発の子宮内膜がん患者に新たな希望を与え、腫瘍の特異的な遺伝子構成に合わせた治療を提供します。このような個別化医療へのシフトは、子宮内膜がん治療をより効果的で患者中心のものにし、転帰を一変させ、腫瘍学の新たな基準を打ち立てています。

どのような革新が子宮内膜がんの治療を強化しているか？

子宮内膜がんの治療における技術革新は、手術手技、標的治療、遺伝子検査の進歩を通じて治療を向上させています。最も重要な開発の1つは、腹腔鏡手術やロボット支援手術のような低侵襲手術法の改善であり、これにより腫瘍を周囲の組織への損傷を少なくして正確に取り除くことができます。これらの技術により、術後の痛みが軽減され、入院期間が短縮され、回復が早まるため、多くの患者にとって手術はそれほど困難な選択肢ではなくなっています。もうひとつの重要な技術革新は、がんの増殖と進行に関与する特定の分子を攻撃する分子標的治療のイントロダクションです。例えば、子宮内膜がんで一般的に変化するPI3K/ACT/mTOR経路を標的とする治療法は、臨床試験で有望視されています。これらの治療は、特に進行した患者や従来の治療法では効果が不十分な患者に対して、より個別化されたアプローチを提供します。さらに、免疫療法は子宮内膜がんの治療において強力な手段として台頭してきており、身体の免疫系を利用してがん細胞とより効果的に闘うことができます。腫瘍の遺伝子検査と分子プロファイリングも治療計画において重要な役割を果たしており、腫瘍医は特定の変異を同定し、個々の患者に最も効果が期待できる治療法を選択することができます。このような技術革新により、子宮内膜がん治療はより正確で侵襲が少なく、各患者のニーズに合わせた治療が可能となり、治療成績とQOLが大幅に向上しています。

子宮内膜がん治療は患者の転帰とQOLにどのような影響を与えますか？

子宮内膜がん治療は、より効果的で低侵襲な選択肢を提供することで、長期的な健康と幸福につながり、患者の転帰とQOLに大きな影響を与えます。早期子宮内膜がんは、多くの場合、手術が主な治療法であり、高度に治療可能です。腹腔鏡手術やロボット支援手術などの手術手技の進歩は、患者の肉体的・精神的負担を最小限に抑え、従来の開腹手術に比べて回復が早く、合併症も少ないです。進行がんや再発がんの患者にとっては、標的療法や免疫療法のイントロダクションが生存率を向上させ、以前は選択肢が限られていたところに新たな希望をもたらしています。これらの治療は延命効果だけでなく、化学療法や放射線療法などのより積極的な治療に伴う副作用を軽減し、その質を向上させています。ホルモン療法は、手術が選択できない場合に用いられることが多く、若い女性の妊孕性を維持しながら効果的に病気を管理できる、侵襲の少ないもう一つの治療法です。最新の子宮内膜がん治療は、各患者の特定のニーズや状況に焦点を当てることで、全体的な体験を向上させ、患者が長生きするだけでなく、治療の旅を通して、またその後もより高い生活の質を維持できるようにしています。

子宮内膜がん治療の成長を促進する動向とは？

子宮内膜がん治療の成長を牽引しているのは、疾患の有病率の増加、個別化医療の進歩、低侵襲治療オプションへの注目の高まりなど、いくつかの動向です。高齢化や肥満の流行などの要因によって子宮内膜がんの罹患率が上昇しているため、効果的な治療オプションに対する需要が高まっています。このため研究開発への投資が活発化し、より効果的で患者の負担が少ない新しい治療法や手術法が生み出されています。遺伝子検査や腫瘍の分子プロファイリングによって、よりオーダーメイドの治療戦略が可能になるため、個別化医療へのシフトも大きな推進力となっています。このアプローチは治療効果を向上させるだけでなく、不必要な副作用を減らすことにもつながり、患者にとってもヘルスケア提供者にとっても魅力的なものとなっています。さらに、回復が早く合併症の少ない治療法を求める患者の要望により、低侵襲治療が重視されるようになってきています。ロボット手術や標的治療における技術革新は、こうした選択肢をより広く利用でき、効果的なものにしています。最後に、腫瘍学における免疫療法の利用拡大により、子宮内膜がん、特に進行がんや抵抗性がんの患者に対する治療の可能性が広がっています。これらの動向は、革新的な治療法や技術の市場成長を促進しながら、患者に新たな希望と転帰の改善をもたらし、市場情勢を再構築しています。

セグメント

製品（化学療法、ホルモン療法）

調査対象企業の例（全38件）

  • Curasight A/S
  • Dheeraj Bojwani Consultants
  • Erasmus MC
  • F. Hoffmann-La Roche AG
  • Florida Cancer Specialists
  • ITM Isotopen Technologien Munchen AG
  • Merck & Co., Inc.
  • Premium Europe
  • Providence Therapeutics Holdings Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP11786

Global Endometrial Cancer Treatment Market to Reach US$46.3 Billion by 2030

The global market for Endometrial Cancer Treatment estimated at US$34.6 Billion in the year 2024, is expected to reach US$46.3 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$31.3 Billion by the end of the analysis period. Growth in the Hormone Therapy segment is estimated at 5.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.5 Billion While China is Forecast to Grow at 4.9% CAGR

The Endometrial Cancer Treatment market in the U.S. is estimated at US$9.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.4 Billion by the year 2030 trailing a CAGR of 4.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Endometrial Cancer Treatment Market - Key Trends and Drivers Summarized

How Is Endometrial Cancer Treatment Revolutionizing Women's Health and Oncology?

Endometrial cancer treatment is revolutionizing women's health and oncology by providing increasingly effective, personalized, and less invasive options for managing one of the most common gynecological cancers. Endometrial cancer, which affects the lining of the uterus, is typically diagnosed in postmenopausal women and has seen rising incidence rates due to factors like obesity and aging populations. Advances in treatment are significantly improving survival rates and quality of life for patients. From surgery and radiation to hormone therapy and targeted treatments, the landscape of endometrial cancer care is evolving rapidly. Surgical techniques, particularly minimally invasive procedures like laparoscopic and robotic-assisted surgery, allow for precise removal of cancerous tissues with shorter recovery times and fewer complications. Additionally, the advent of targeted therapies and immunotherapy is offering new hope for patients with advanced or recurrent endometrial cancer, tailoring treatment to the specific genetic makeup of their tumors. This shift towards personalized medicine is making endometrial cancer treatment more effective and patient-centered, transforming outcomes and setting new standards in oncology.

What Innovations Are Enhancing the Treatment of Endometrial Cancer?

Innovations in the treatment of endometrial cancer are enhancing care through advancements in surgical techniques, targeted therapies, and genetic testing. One of the most significant developments is the improvement in minimally invasive surgical methods, such as laparoscopic and robotic-assisted surgeries, which allow for the precise removal of tumors with less damage to surrounding tissues. These techniques reduce postoperative pain, shorten hospital stays, and lead to quicker recoveries, making surgery a less daunting option for many patients. Another key innovation is the introduction of targeted therapies, which attack specific molecules involved in cancer growth and progression. For instance, therapies targeting the PI3K/AKT/mTOR pathway, commonly altered in endometrial cancer, are showing promise in clinical trials. These treatments offer a more personalized approach, particularly for patients with advanced disease or those who do not respond well to conventional therapies. Additionally, immunotherapy is emerging as a powerful tool in treating endometrial cancer, harnessing the body's immune system to fight cancer cells more effectively. Genetic testing and molecular profiling of tumors are also playing a critical role in treatment planning, allowing oncologists to identify specific mutations and select therapies that are most likely to be effective for individual patients. These innovations are making endometrial cancer treatment more precise, less invasive, and better tailored to the needs of each patient, significantly improving outcomes and quality of life.

How Does Endometrial Cancer Treatment Impact Patient Outcomes and Quality of Life?

Endometrial cancer treatment has a profound impact on patient outcomes and quality of life by offering more effective and less invasive options that lead to better long-term health and well-being. Early-stage endometrial cancer is often highly treatable, with surgery being the primary mode of treatment. Advances in surgical techniques, such as laparoscopic and robotic-assisted procedures, minimize the physical and emotional toll on patients, leading to faster recoveries and fewer complications compared to traditional open surgeries. For patients with more advanced or recurrent cancer, the introduction of targeted therapies and immunotherapy is improving survival rates and offering new hope where options were previously limited. These treatments are not only extending life but also improving its quality by reducing the side effects associated with more aggressive treatments like chemotherapy and radiation. Hormone therapy, often used in cases where surgery is not an option, offers another less invasive treatment pathway that can effectively manage the disease while preserving fertility in younger women. By focusing on the specific needs and circumstances of each patient, modern endometrial cancer treatment is enhancing the overall experience, ensuring that patients not only live longer but also maintain a higher quality of life throughout and after their treatment journey.

What Trends Are Driving Growth in Endometrial Cancer Treatment?

Several trends are driving growth in endometrial cancer treatment, including the increasing prevalence of the disease, advancements in personalized medicine, and the growing focus on minimally invasive treatment options. The rising incidence of endometrial cancer, driven by factors such as aging populations and the obesity epidemic, is leading to greater demand for effective treatment options. This has spurred investment in research and development, resulting in new therapies and surgical techniques that are more effective and less burdensome for patients. The shift towards personalized medicine is also a significant driver, as genetic testing and molecular profiling of tumors allow for more tailored treatment strategies. This approach not only improves the effectiveness of treatment but also reduces unnecessary side effects, making it more appealing to patients and healthcare providers alike. Additionally, there is a growing emphasis on minimally invasive treatments, driven by patient demand for options that offer quicker recovery times and fewer complications. Innovations in robotic surgery and targeted therapies are making these options more widely available and effective. Finally, the increasing use of immunotherapy in oncology is expanding treatment possibilities for endometrial cancer, particularly for patients with advanced or resistant forms of the disease. These trends are reshaping the landscape of endometrial cancer treatment, offering new hope and improved outcomes for patients while driving growth in the market for innovative therapies and technologies.

SCOPE OF STUDY:

The report analyzes the Endometrial Cancer Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Chemotherapy, Hormone therapy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 38 Featured) -

  • Curasight A/S
  • Dheeraj Bojwani Consultants
  • Erasmus MC
  • F. Hoffmann-La Roche AG
  • Florida Cancer Specialists
  • ITM Isotopen Technologien Munchen AG
  • Merck & Co., Inc.
  • Premium Europe
  • Providence Therapeutics Holdings Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Endometrial Cancer Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Endometrial Cancer Driving Demand for Effective Treatments
    • Advancements in Targeted Therapies and Immunotherapy Enhancing Treatment Efficacy
    • Growing Adoption of Minimally Invasive Surgeries for Cancer Treatment
    • Development of Novel Chemotherapeutic Agents and Drug Combinations
    • Integration of Advanced Imaging Technologies for Early Diagnosis and Treatment Planning
    • Adoption of Digital Health Records Improving Patient Management
    • Future Directions: Nanotechnology and Its Potential in Drug Delivery Systems for Cancer
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Endometrial Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Endometrial Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Hormone therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 10: World Endometrial Cancer Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: USA 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: Canada 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
  • JAPAN
    • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: Japan 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
  • CHINA
    • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: China 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
  • EUROPE
    • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Endometrial Cancer Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Europe 15-Year Perspective for Endometrial Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Europe 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
  • FRANCE
    • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: France 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
  • GERMANY
    • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Germany 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Italy 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: UK 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Rest of Europe Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Rest of Europe 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Endometrial Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Asia-Pacific Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Asia-Pacific 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 47: Rest of World Recent Past, Current & Future Analysis for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of World Historic Review for Endometrial Cancer Treatment by Product - Chemotherapy and Hormone therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Rest of World 15-Year Perspective for Endometrial Cancer Treatment by Product - Percentage Breakdown of Value Sales for Chemotherapy and Hormone therapy for the Years 2015, 2025 & 2030

IV. COMPETITION